Vyondys 53 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 113 | Muscular dystrophy | 1 |
113. Muscular dystrophy
Clinical trials : 622 / Drugs : 485 - (DrugBank : 99) / Drug target genes : 59 - Drug target pathways : 168
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04708314 (ClinicalTrials.gov) | October 31, 2020 | 21/9/2020 | An Open-Label Study of Golodirsen in Non-Ambulant Patients With Duchenne Muscular Dystrophy | An Open-Label Study to Evaluate the Safety of Golodirsen in Non-Ambulant Patients With Duchenne Muscular Dystrophy | Duchenne Muscular Dystrophy | Drug: Golodirsen 50 MG/1 ML Intravenous Solution [VYONDYS 53] | Rare Disease Research, LLC | Sarepta Therapeutics, Inc. | Terminated | 7 Years | N/A | Male | 2 | Phase 4 | United States |